Oslo, 17 June 2016. Reference is made to the stock exchange announcement made by Navamedic ASA ("NAVA" or the "Company") on 13 June 2016 regarding the Company entering into a strategic partnership and 8-year distribution agreement with TopRidge Pharma Limited ("TopRidge"), an associated company of Tibet Rhodiola Pharmaceutical Holding Co ("Tibet Pharma"), including an investment to be made in the Company by TopRidge's wholly-owned subsidiary, TopRidge Pharma (Ireland) Limited ("TopRidge Ireland").
The share capital increase related to the 1,417,522 new shares issued to TopRidge Ireland has been registered with the Norwegian Register of Business Enterprises and the Company's share capital is now NOK 10,867,673 divided into 10,867,673 shares, each with nominal value NOK 1.
The new shares issued to TopRidge Ireland will be issued on a separate ISIN and not be tradable on the Oslo Stock Exchange until the Company has prepared and published a listing prospectus to be approved by the Financial Supervisory Authority of Norway (Finanstilsynet), expected in August 2016.
Contact Navamedic ASA:
CFO Toril Ås
This information is subject of the disclosure requirements pursuant to section 5-8 of the Norwegian Securities Trading Act.